Population pharmacokinetics of cisplatin in adult cancer patients

By Jongh Felix   Gallo James   Shen Meiyu   Verweij Jaap   Sparreboom Alex  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 2, 2004-08 ,pp. : 105-112

Springer Publishing Company

Access to resources Recommend Favorite

Enhancement of Antitumour Activity of Cisplatin by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy] Ethanamine.HCl in Human Ovarian Cancer Cells with Intrinsic or Acquired Resistance to Cisplatin

By Kudoh K.   Kikuchi Y.   Hiramatsu H.   Hirata J.   Yamamoto K.   Kita T.   Nagata I.  

European Journal of Cancer, Vol. 33, Iss. 1, 1997-01 ,pp. : 122-128

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

By Berger K.   Fischer T.   Szucs T.D.  

European Journal of Cancer, Vol. 34, Iss. 12, 1998-11 ,pp. : 1894-1901

Elsevier

Access to resources Recommend Favorite

Electrochemotherapy of tumours resistant to cisplatin - a study in a murine tumour model

By Cemazar M.   Miklavcic D.   Mir L.M.   Belehradek J.   Bonnay M.   Fourcault D.   Sersa G.  

European Journal of Cancer, Vol. 37, Iss. 9, 2001-06 ,pp. : 1166-1172

Elsevier

Access to resources Recommend Favorite

Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 3, 2005-05 ,pp. : 251-265

Bentham Science Publishers

Access to resources Recommend Favorite